FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to allergology, and can be used for reduction of number of basophils in humans. For this patient gets approximately 0.03 mg/kg of monoclonal, chimeric, humanized or human antibody, which binds interleukin receptor IL-5R and includes Fc region of immunoglobulin, not containing fucose. Application of this antibody reduces number of basophils in peripheral blood in human circulatory system 24 hours after administration.
EFFECT: application of given method enables to induce stable reduction of basophils by single intravenous dose of antibody.
9 cl, 1 tbl, 14 ex, 31 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR REDUCING EOSINOPHIL COUNT | 2008 |
|
RU2519227C2 |
| METHODS FOR REDUCING EXACERBATION RATES OF ASTHMA USING OF BENRALIZUMAB | 2014 |
|
RU2676333C2 |
| METHODS FOR INCREASING FORCED EXPIRATORY VOLUME IN ASTHMATIC PATIENTS USING BENRALIZUMAB | 2014 |
|
RU2703568C2 |
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| DIAGNOSTICS AND TREATMENT METHODS ASSOCIATED WITH TH2 INHIBITION | 2011 |
|
RU2737245C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST | 2018 |
|
RU2793745C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR NORMALIZING ASTHMA SYMPTOMS USING BENRALIZUMAB | 2014 |
|
RU2728578C2 |
| THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES | 2019 |
|
RU2795180C2 |
| GATA-3 INHIBITORS FOR USE IN TREATING TH2-INDUCED ASTHMA | 2016 |
|
RU2720988C2 |
